Review source-labeled screening guidance, prepare questions and records, confirm benefits and save a checklist for results and next steps.
Arrange care with a primary care clinician, OB/GYN or another appropriately qualified professional. Discuss access, communication preferences, consent and who coordinates screening and follow-up. Verify referral requirements with your own plan.
Gather prior cervical test and breast imaging reports, follow-up or treatment records, operations including whether the cervix was removed, relevant family cancer history and current medicines. Note pregnancy possibility, reproductive goals, menopause concerns and symptoms you want assessed.
Use the source-labeled examples below to prepare questions, then confirm the current guideline and test with your clinician. Record the test type, why it applies and the next date. High-risk histories and symptoms may need a different pathway from routine screening.
Raise contraception, pregnancy planning or care, menstrual changes, sexual health, menopause symptoms and mental health as relevant. Ask which issues need a separate appointment or referral and how results will be shared. Review medicine and supplement questions with the treating professional.
Ask for the precise test and planned services, network participation, benefit requirements and an itemized patient estimate. Confirm whether additional investigations or a separately billed problem visit could change the amount. Obtain test-specific preparation instructions and discuss comfort, consent or accessibility needs.
Confirm when results are expected and contact the ordering team if they are late. For an abnormal cervical result, follow-up depends on the exact result, prior screening, previous treatment and personal factors; it may involve repeat testing, colposcopy or treatment. Save the agreed action and deadline and confirm completion.
Loading your checklist…
Checked September 10, 2026. These examples name USPSTF guidance and apply to routine screening, not diagnosis of symptoms or surveillance after an abnormal finding.
| Screening | Source-labeled example | Important boundaries |
|---|---|---|
| Breast — USPSTF 2024 | Mammography every 2 years at ages 40–74 for the recommendation’s population, including women and other people assigned female at birth. | Known high-risk genetic syndromes, prior breast cancer or high-risk lesions, or young-age high-dose chest radiation need a different plan. Evidence is insufficient for routine screening at 75+ or supplemental ultrasound/MRI solely for dense breasts; discuss individually. |
| Cervical — USPSTF 2018 final statement | For average-risk people with a cervix: ages 21–29, cytology every 3 years; ages 30–65, cytology every 3 years OR primary high-risk HPV testing every 5 years OR cotesting every 5 years. | The USPSTF page lists an update in progress. Stopping after 65 depends on adequate prior screening and risk. After cervix removal, prior high-grade lesions/cancer matter. Immunocompromise, DES exposure or previous high-grade lesions/cancer require individualized care. Confirm the current guideline and test option. |
| Bone — USPSTF 2025 | Screen women 65+ and postmenopausal women younger than 65 at increased fracture risk after clinical risk assessment. | Known osteoporosis, fragility fractures, secondary causes or bone-loss medicines need separate care. There is no universal two-year repeat interval in this recommendation; agree timing from findings and risk. |
Use these prompts to get a plan you can act on.
| Question | Record before leaving |
|---|---|
| Which test applies to me? | Guideline, test type, relevant history and next date |
| What happens if the result is abnormal? | Ordering team, contact route and follow-up process |
| What could I be charged? | Exact services, benefit confirmation and itemized estimate |
| How can the visit work for me? | Consent, comfort, language, access and preparation needs |
| What remains unresolved? | Named owner and deadline for each next action |
The linked USPSTF statements distinguish populations and evidence gaps. The cervical source remains a final 2018 statement with an update in progress at this review; a draft is not presented here as a final recommendation.
NCI explains why follow-up after an abnormal cervical test depends on current and past results and individual factors. Verify the precise services with the care team and plan; a screening recommendation alone is not a coverage guarantee.
Return to your saved checklist to close unfinished tasks. Keep actual findings, documents and medical identifiers in a private record system, not in shared device notes.
Bring the source and your previous records to the conversation. A recommendation, appointment, insurance benefit and completed follow-up are separate pieces of the plan.